Lastly, our results are compatible with recent studies, which report in patients with NSCLC the encouraging therapeutic results shown by treatment strategies involving the combination of MEK inhibitors with other therapies such as BRAF inhibition, immunotherapy or chemotherapy [118]. Here, BRAF is linked to non-small cell lung carcinoma.